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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterized by symptoms of inattention, hyperactivity, and impulsivity that cause functional 
impairment. Recent research indicates that symptoms persist into adulthood in the majority 
of cases, with prevalence estimates of approximately 5% in the school age population and 
2.5%–4% in the adult population. Although students with ADHD are at greater risk for academic 
underachievement and psychosocial problems, increasing numbers of students with ADHD are 
graduating from high school and pursuing higher education. Stimulant medications are consid-
ered the first line of pharmacotherapy for individuals with ADHD, including college students. 
Although preliminary evidence indicates that prescription stimulants are safe and effective for 
college students with ADHD when used as prescribed, very few controlled studies have been 
conducted concerning the efficacy of prescription stimulants with college students. In addition, 
misuse of prescription stimulants has become a serious problem on college campuses across 
the US and has been recently documented in other countries as well. The purpose of the pres-
ent systematic review was to investigate the efficacy of prescription stimulants for adolescents 
and young adults with ADHD and the nonmedical use and misuse of prescription stimulants. 
Results revealed that both prostimulant and stimulant medications, including lisdexamfetamine 
dimesylate, methylphenidate, amphetamines, and mixed-amphetamine salts, are effective at 
reducing ADHD symptoms in adolescents and adults with ADHD. Findings also suggest that 
individuals with ADHD may have higher rates of stimulant misuse than individuals without the 
disorder, and characteristics such as sex, race, use of illicit drugs, and academic performance 
are associated with misuse of stimulant medications. Results also indicate that individuals both 
with and without ADHD are more likely to misuse short-acting agents than long-acting agents. 
These findings have implications for intervention, prevention, and future research.
Keywords: ADHD symptomatology, pharmacotherapy, nonmedical stimulant use, lisdexam-
fetamine, methylphenidate, amphetamine 
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterized by symptoms of inattention, hyperactivity, and impulsivity that cause 
functional impairment.1 Previously, ADHD was believed to be primarily a disorder 
of childhood that would be outgrown with the onset of puberty. Recent research, 
however, indicates that symptoms persist into adulthood in the majority of cases, with 
prevalence estimates of approximately 5% in the school age population and 2.5%–4% 
in the adult population.1–4 Academic problems are prevalent among children and 
adolescents with ADHD and are associated with inattention and difficulty remain-
ing seated, following directions, and completing assignments.5 In addition, children 
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and adolescents with ADHD often demonstrate disruptive, 
defiant, and hostile behavior.6,7 Given these  academic and 
behavioral difficulties, children and adolescents with ADHD 
are more likely than their non-ADHD peers to receive lower 
grades, fall behind academically, receive special education 
services, repeat grades, and drop out of high school and are 
less likely to pursue college.5,8 Research suggests, however, 
that the symptoms of ADHD are often manifested differently 
in adolescence compared with in childhood. For example, 
symptoms of hyperactivity tend to decrease in adolescence 
relative to childhood and instead may be manifested as symp-
toms of cognitive or internal restlessness.9–11 Adolescents with 
ADHD, however, continue to demonstrate similar levels of 
impairment as younger children with ADHD, including aca-
demic underachievement and difficulties with peers and social 
relationships, as well as various high-risk behaviors, including 
reckless driving and sexual behavior and substance use.12
Despite these impairments, students with ADHD are 
increasingly graduating from high school and attending 
college.13 However, information is lacking concerning the 
exact prevalence of ADHD among college students, due to 
privacy protection for students with disabilities under the 
Americans with Disabilities Act of 1990 and because many 
college students who meet diagnostic criteria for ADHD may 
not have been diagnosed with the disorder.14,15 Therefore, 
more information is sorely needed regarding the prevalence 
of the disorder in the college population and its impact on 
student functioning. Several investigations have examined the 
prevalence of ADHD and the functioning of college students 
with ADHD symptomatology, most of which have relied on 
student self-report. For example, Weyandt et al16 conducted the 
first study assessing ADHD symptomatology among college 
students and found that approximately 2.5%–8.7% of partici-
pants reported significant ADHD symptoms, depending on the 
criteria employed. More recent estimates are similar to those 
of Weyandt et al, indicating that approximately 2%–10% of 
college students have significant ADHD symptoms and that 
approximately 50% of students who receive disability services 
do so because of ADHD.15,17–19
In terms of the academic and psychosocial functioning of 
college students with ADHD, Norwalk et al20 found that stu-
dents with ADHD had greater difficulty with college adjust-
ment and poorer study habits and study skills than  students 
without the disorder. Similarly, Shaw-Zirt et al21 found that 
college students with ADHD, matched with non-ADHD peers 
on age, sex, and grade point average (GPA) (a measure of 
academic performance), reported poorer academic, social, 
and emotional adjustment than non-ADHD participants. 
Other studies have revealed that college students with ADHD 
tend to have lower GPAs, higher rates of academic probation, 
and poorer test-taking strategies and are less likely to gradu-
ate from college.2,22–24 Self-reported psychological distress 
also appears to be more common among college students 
with ADHD than among those without the disorder, includ-
ing poorer self-esteem and increased levels of depression 
and anxiety.21,25–27 Collectively, these findings indicate that 
students with ADHD and elevated ADHD symptomatology 
are beset by various challenges in the college environment. 
To improve the outcomes of college students with ADHD, 
proper identification of the disorder is crucial so that effec-
tive prevention and intervention strategies may be developed 
and implemented.
Medical and nonmedical use  
of prescription stimulants
Pharmacotherapy is the primary treatment option for 
children, adolescents, and adults with ADHD, including 
college students.28,29 US Food and Drug Administration 
(FDA)-approved medications for ADHD include 1) stimu-
lants such as methylphenidate (MPH) (eg, Ritalin [Novartis 
International AG, Basel, Switzerland],  Concerta [Janssen 
Pharmaceuticals Inc., Titusville, NJ, USA]), dextroamphet-
amine (D-AMP) (eg, Adderall [Shire plc, Dublin, Ireland], 
Dexedrine [GlaxoSmithKline plc, London, UK]), and 
lisdexamfetamine dimesylate (LDX) (eg, Vyvanse [Shire 
Inc., Wayne, PA, USA]), a prostimulant; and 2) nonstimu-
lants (eg,  atomoxetine, [Strattera; Eli Lilly and Company, 
Indianapolis, IN, USA]). 
Nonstimulants (eg, atomoxetine) have been demonstrated 
to be safe and effective for improving ADHD symptoms 
among children, adolescents, and adults.30–33 Nonstimulants 
have been found to be effective for individuals who do not 
respond to stimulants and have also been recommended for 
treating patients with ADHD who have comorbid substance 
use disorder (SUD). Nonstimulants, unlike stimulants, pri-
marily affect the norepinephrine neurotransmitter system 
rather than the dopaminergic system and consequently have 
a lower potential for abuse than stimulant medications. 
Stimulant medications, however, remain the first line of 
pharmacotherapy for individuals with ADHD.28,29,32 An 
extensive body of literature attests that stimulant medication, 
when used as prescribed, is safe and efficacious for improv-
ing attention and decreasing hyperactivity and impulsivity 
symptoms.34–42 Although individuals with ADHD may greatly 
benefit from prescription stimulant medication, given their 
abuse potential when not taken as prescribed, prescription 
stimulants have been classified as schedule II medications by 
the FDA. A schedule II classification indicates that although 
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the medication has been approved for medical use, it has a 
high potential for abuse, which, in turn, may lead to physio-
logical and/or psychological dependence.43
Numerous studies have documented that the nonmedi-
cal use of prescription stimulants, defined here as the use of 
stimulant medication in the absence of a valid prescription 
and use of prescription stimulants other than as prescribed, 
is a growing problem on college campuses, and college 
students typically report that stimulant medication is easy 
to obtain on campus.44–52 Indeed, large numbers of students 
claim to have engaged in the nonmedical use of prescription 
stimulants, which is reflected in lifetime prevalence rates of 
prescription stimulant misuse ranging from 5% to nearly 
34% of students.53,54 Researchers have speculated that this 
increase may, in part, be explained by increasing numbers 
of college students receiving stimulant medication treatment 
for ADHD who may be distributing their medication to their 
peers, who may, in turn, misuse it.44,49 Due to the significant 
health risks associated with the nonmedical use of prescrip-
tion stimulants, this behavior poses a serious public health 
issue.55 Consequently, studies have attempted to elucidate the 
characteristics of prescription stimulant misuse as well as risk 
and protective factors associated with this behavior.
The most commonly reported and the most strongly 
endorsed reason for taking prescription stimulants nonmedi-
cally is to improve attention and alertness while studying, 
taking exams, and writing papers: ie, cognitive and academic 
enhancement.44,45,49,52,53 Research has also identified several 
risk factors for stimulant misuse, including demographic 
variables such as sex, ethnicity, and psychological risk 
 factors, such as depressive symptomatology and symptoms 
of inattention. The identification of malleable predictors such 
as the academic and psychosocial functioning of students is 
particularly important for prevention and intervention strate-
gies for prescription stimulant misuse.56–58
Purpose of the present study
Given the positive association between psychological  factors, 
ADHD symptoms, and the nonmedical use of prescrip-
tion stimulants, and that college students report misusing 
stimulants primarily to enhance their cognitive and academic 
functioning, it is highly plausible that, by doing so, students 
are trying to compensate for the struggles they encounter 
in the college environment. In fact, some researchers have 
hypothesized that college students may be using prescription 
stimulants nonmedically as a coping strategy to treat ADHD 
symptoms: ie, to “self-medicate”.49,57 Although preliminary 
evidence indicates that prescription stimulants are safe and 
effective for college students with ADHD when used as 
prescribed, very few controlled studies have been conducted 
on the efficacy of prescription stimulants for college student 
functioning specifically.37 The question that arises, then, is 
whether the medical use of prescription stimulants leads to 
reductions in symptoms and improved academic and psycho-
social outcomes. Further, is the medical use of prescription 
stimulants associated with increased nonmedical use of these 
medications? What is the scope of prescription stimulant 
misuse among college students? Are certain types of medica-
tions associated with greater potential for misuse than others? 
Answers to these questions will greatly inform both the treat-
ment of ADHD among college students and prevention and 
intervention efforts aimed at reducing the nonmedical use of 
prescription stimulants on college campuses.
The present study attempted to answer these questions 
by conducting a systematic review of the literature concern-
ing studies that investigated 1) the efficacy of prescription 
stimulants for adolescents and adults, including college 
students, with ADHD and 2) the nonmedical use and misuse 
of prescription stimulants.
Methods
Search and retrieval
A systematic literature review was conducted according 
to Okoli and Schabram’s59 eight-step guide. Accordingly, 
all researchers were trained in the protocol for searching 
and identifying relevant articles. Although the first study 
to identify stimulant misuse was conducted in 2000 by 
Babcock and Byrne,46 a substantial number of studies 
addressing stimulant misuse appeared in 2002. Therefore, 
we attempted to identify and retrieve all empirical studies 
published after 2002 that examined the efficacy of stimulants 
and nonstimulants and stimulant misuse with adolescents 
and adults. The search and retrieval process included a com-
prehensive search of the following bibliographic databases: 
PsycINFO,  PsycARTICLES®, MEDLINE, and Science-
Direct. Keywords and eligibility criteria were established 
separately for each subject. In order to identify and retrieve 
empirical studies that examined the efficacy of stimulants 
among adolescents and adults, the following keywords 
were used: “efficacy” + “stimulants”, “efficacy” + “Ritalin”, 
“efficacy” +  “Adderall”, “efficacy” + “Concerta”, “ADHD” + 
 “Ritalin”, “ADHD” + “Adderall”, and “ADHD” +  “Concerta”. 
 Keywords used to identify research examining the efficacy 
of  nonstimulants and prostimulants among  adolescents 
and adults included the  following:  “efficacy” + “nonstimu-
lants”,  “efficacy” +  “Strattera”, “efficacy” + “Vyvanse”, 
and  “efficacy” +  “prostimulant”. Finally, keywords used 
to identify research examining stimulant misuse among 
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adolescents and adults were:  “prescription stimulant” + 
“misuse”, “prescription stimulant” + “illicit”, “methylpheni-
date” +  “misuse”, “methylphenidate” + “illicit”, “prescription 
stimulants” + “nonmedical”, and “methylphenidate” + 
“nonmedical”.
eligibility criteria
Studies for all search subjects were selected for review based 
on the following criteria.
 1.  The study was published in English.
 2.  The study was published no earlier than 2002.
 3.  The study included a minimum sample size of 
20 subjects.
 4.  The study used an original dataset (meta-analyses and 
reviews were excluded).
 5.  The s tudy was re la t ional ,  exper imental ,  or 
quasiexperimental.
 6.  The study could be conducted worldwide.
 7.  The sample included adolescents (ie, participants with a 
mean age of $12 years) and/or adults. Note that studies 
including both children and adolescents were included if 
the mean age of participants was $12 years. Studies that 
did not report the participants’ mean age and included 
samples with a majority of participants aged ,12 years 
were excluded.
 8.  The sample included human subjects only and included 
no special groups except for persons with ADHD and 
learning disabilities.
 9.  The study used only FDA-approved medication 
for ADHD.
10.  Eligibility criteria were established specif ically 
for research examining the efficacy of stimulants, 
 prostimulants, and nonstimulants.
11.  The sample included a control group (guanfacine studies 
were excluded, as well as studies examining efficacy of 
nicotinic agonists).
Results
The search process resulted in identifying 2,103 sources, of 
which 76 met eligibility criteria. Specifically, nine studies 
examined the efficacy of LDX, 14 explored the efficacy of 
MPH, three assessed the efficacy of amphetamine (AMPH), 
three explored the efficacy of both MPH and AMPH in 
 adolescents and adults, and 47 examined stimulant misuse 
among adolescents and adults. Although included in the 
initial search process, no studies examining the efficacy 
of nonstimulants met eligibility criteria for the present 
review.
Efficacy of prostimulants  
for adolescents and adults
As seen in Table 1, all of the included studies (n=9) 
demonstrated a significant improvement in the measured 
outcomes from LDX compared with placebo. Six of the nine 
included studies reported effect sizes, all of which (based 
on Cohen’s estimates of small, medium, and large) reported 
medium to large LDX-related effects for improvement in 
ADHD and related symptoms.35,37,60–64 Although the majority 
of studies examined LDX effects among adults, only one 
study examined its efficacy among a sample of adolescents. 
Specifically, Findling et al65 reported that at varying doses 
(30, 50, and 70 mg/day), LDX was more effective at treat-
ing ADHD than placebo. Regarding adults with ADHD, 
improvements from LDX have been reported for quality of 
life, performance productivity, and executive function.35,64,66 
Large effects from LDX on improved executive function 
were also demonstrated in college students with and without 
ADHD.37 Furthermore, LDX was associated with reduced 
ADHD symptoms compared with placebo in a sample of 
college students and two different samples of adults.37,61,62 
Although higher doses of LDX related to greater improve-
ment in the reduction of ADHD symptoms in two studies, in 
one study differences between doses were not observed.37,61,62 
The maintenance of efficacy of LDX compared with placebo 
during a 2-week randomized withdrawal phase was also dem-
onstrated to be effective in a sample of adults with ADHD.67 
Finally, findings suggest that LDX may be effective for 
treating individuals with comorbid ADHD and depression 
or SUD and in reducing ADHD symptoms.63
The most common side effects reported by participants 
in studies investigating the efficacy of LDX included a 
decreased appetite, weight loss, dry mouth, insomnia, nau-
sea, diarrhea, dizziness, headache, nasal congestion, feeling 
jittery, and anxiety. Mild to moderate adverse treatment-
related effects were generally reported by 5% or fewer treat-
ment group participants and included insomnia, tachycardia, 
irritability, fatigue, increased blood pressure/hypertension, 
upper respiratory tract infections, anxiety, decreased libido, 
and dyspnea. No deaths were reported in any of the studies. 
The results of most LDX studies led to the conclusion that 
the drug has a safety profile consistent with previous studies 
and other long-acting stimulants.
Efficacy of MPH and AMPH  
for adolescents and adults
Although research examining the efficacy of LDX is in its 
early stages, numerous studies have examined the efficacy 
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of MPH, AMPH, and mixed amphetamine salts (MAS). The 
included research studies examined the effects of these stimu-
lants among samples of adolescents (n=5), one of which also 
included children, and adults (n=15) (see Table 2). The vast 
majority of studies (n=14) specifically examined the effects 
of some form of MPH, whereas three studies examined MAS, 
and the remaining studies (n=3) examined a combination of 
MPH and MAS or AMPH. Regardless of the medication 
examined, all of the included studies reported statistically sig-
nificant positive effects for stimulant medication  compared 
with placebo, and effect sizes ranging from small to large 
based on Cohen’s estimates of effect size.60 A total of 14 out 
of 20 included studies reported effect sizes. Of the studies 
reporting effect sizes for positive effects from stimulant 
medication, most effect sizes ranged from medium to large, 
with two studies reporting small to medium effects.40,68–77 One 
study reported effect sizes regarding the interaction effects 
of differences between sex and medication dose, with no 
significant interactions found. Effect sizes ranged from very 
small (partial η2 as low as 0.00) to small.78
Studies assessing the effects of MPH, dextroamphet-
amine extended release (d-MPH-ER), MPH long-acting 
or extended release (MPH-ER), multilayer-release MPH, 
and MAS, including triple-bead MAS and MAS extended 
release (MAS-ER), have demonstrated reductions in ADHD 
symptoms among adult samples.34,40,69–72,74–76,79–82 For example, 
Biederman et al83 reported that adults with ADHD taking 
osmotic release oral system (OROS)-MPH, compared with 
those taking a placebo, demonstrated reduced symptoms of 
inattention and hyperactivity/impulsivity specifically. Ado-
lescents taking MAS-ER and MPH-ER have also been shown 
to demonstrate reduced ADHD symptoms.73,84
Regarding the effective dose for improvements in 
ADHD symptoms, doses of MPH-ER of 36–108 mg/day 
and 40–80 mg/day have been shown to be effective.34,40 
Similarly, two studies reported that higher doses of MPH-ER 
and d-MPH-ER were more effective than lower doses at 
reducing ADHD symptoms among adults with ADHD.70,74 
Among adolescents, higher doses, compared with lower 
doses, of d-MPH-ER and MAS-ER have also been shown 
to relate to improvement of ADHD symptoms.75 Rösler 
et al,76 however, reported that even at low to moderate doses 
(10–60 mg/day), MPH-ER was effective at reducing ADHD 
symptoms and that these effects were sustained during a 
24-week follow-up.
In addition to ADHD symptoms, studies have shown that 
MPH and MPH-ER may improve cognition and emotional 
symptoms, and triple-bead MAS may enhance executive T
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functions and quality of life among adults.68,77,81 For example, 
Rösler et al77 reported on a multicenter 24-week study and 
found that among a sample of adults with ADHD, taking 
MPH-ER was associated with improvement in emotional 
symptoms, obsessive–compulsive symptoms, and problems 
with self-concept. Among adolescents, one study reported 
that within a sample of 35 adolescents, those taking either 
OROS-MPH or amphetamine extended release (AMPH-ER) 
(Adderall XR) demonstrated improved neuropsychological 
functioning compared with those taking placebo.85 Finally, 
MPH-ER and AMPH-ER have been demonstrated to be 
equally effective at improving symptoms among male and 
female adolescents with ADHD.78
Regarding side effects in studies investigating the efficacy 
of D-AMP and MPH, participants most commonly reported 
decreased appetite, weight loss, headache, insomnia, abdomi-
nal pain, dizziness, nervousness, emotional lability, and dry 
mouth. Approximately half of the studies (n=12) found that 
a majority of participants reported at least one side effect; 
however, mild to moderate adverse treatment-related effects 
were generally reported by #5% treatment group partici-
pants and included decreased weight, insomnia, tachycardia, 
palpitation, irritability, fatigue, increased blood pressure/
hypertension, and anxiety. No deaths were reported in any 
of the studies. The results of most stimulant studies led to 
the conclusion that the drug has a safety profile consistent 
with previous research.86
Stimulant misuse among  
adolescents and adults
The efficacy of prescription stimulants among adolescents 
and adults with ADHD has been well documented, but the 
effects of these medications among populations without 
ADHD are unclear. Despite a lack of empirical evidence 
of stimulant effectiveness in individuals without ADHD, 
numerous studies have documented the misuse of prescrip-
tion stimulants among college students without the disorder. 
Indeed, the present review retrieved more research studies 
pertaining to stimulant misuse (n=47) than the combined 
number of included studies assessing the efficacy of LDX, 
MPH, AMP, and MAS combined (see Table 3). The primary 
foci of the retrieved studies examining stimulant misuse 
varied. For example, some studies reported on prevalence 
rate estimates, others examined characteristics of individuals 
most susceptible to stimulant misuse, and others reported 
primarily on student opinions, such as ethical implications of 
stimulant misuse. Most of the studies, however, reported on 
some combination of these factors. Therefore, a systematic 
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assessment and inclusion of effect sizes was beyond the scope 
of the present article.
The studies reviewed indicate that prescription stimu-
lant misuse is a growing problem across adolescent and 
adult populations. Estimates of lifetime prevalence range 
from 7.1% to 29% among adults, 5.3% to 55% among col-
lege students, and 1.7% to 4.5% among adolescents.53,87–92 
Although estimates of stimulant misuse prevalence appear 
to be relatively low among general adolescent samples, 
estimates of stimulant misuse among adolescents using other 
substances (23%–31%) and among adolescents and adults 
receiving treatment for ADHD (14%) are much higher.91–97 
Estimates of lifetime stimulant misuse also appear to increase 
as adolescents reach higher grade levels. For example, among 
high school seniors, McCabe and West98 reported that nearly 
10% admitted to using prescription stimulants nonmedically 
at least once. Similarly, lifetime prevalence estimates in col-
lege have been shown to grow as students reach their final 
years of school. Garnier-Dykstra et al56 reported that although 
only 13.3% of first year students reported stimulant misuse, 
by their fourth year 31% reported misuse.
In addition to college level, lifetime estimates of stimulant 
misuse may vary according to several other variables. For 
example, prevalence of stimulant misuse specifically for 
cognitive enhancement was estimated to be ,2% in a sample 
of preuniversity (students preparing to attend university) 
and university students in Germany, but prevalence esti-
mates of stimulant misuse for the purpose of weight loss 
has been reported to be nearly 12%.99,100 Studies assessing 
stimulant misuse among general samples of college stu-
dents have reported rates between approximately 8% and 
34%.54,101,102 Much higher estimates of stimulant misuse 
have been reported among samples of college students with 
ADHD (43%) or with prescriptions for stimulant medication 
(45.2%). The highest estimates of prevalence of stimulant 
misuse among college students (55%), however, have been 
reported among a sample of fraternity members.90,103,104
Among medical students, lifetime prevalence esti-
mates for engaging in prescription stimulant misuse have 
ranged between 9%–10% and 18%.105–107 Moderate lifetime 
 prevalence estimates of stimulant misuse have also been 
reported among undergraduate and graduate health care stu-
dents (11%), dental and dental hygiene students (12.4%), and 
general samples including both undergraduate and graduate 
students (16.2%–17.5%).50,108–110
Compared with adolescents and college students, very 
few studies have addressed prevalence estimates of stimu-
lant misuse among adults aged $18 years outside of the 
university setting. Novak et al87 reported that 2% of the 
4,297 adults sampled indicated that they had engaged in 
nonmedical use of ADHD medications in the past year and 
7.1% in their lifetime. Pilkinton and Cannatella88 reported 
similar rates (7.1%) for lifetime prevalence estimates among 
a sample of both adolescents and adults. However, estimates 
of stimulant misuse prevalence among adults with prescrip-
tions for stimulant medications have yielded much higher 
rates (29%), similar to adolescent populations.89 Finally, 
Lensing et al111 explored physician and adult patient agree-
ment regarding prescription stimulant misuse and diversion 
and found that ,1% of physicians suspected their patients 
of diversion and ,2% of the adults themselves reported 
diversion of prescription stimulants, yielding a high level 
of agreement between the two.
Studies examining characteristics of students engaging in 
stimulant misuse have yielded relatively consistent findings 
regarding sex and race/ethnicity. Although multiple studies 
reported that male students have indicated higher rates of 
lifetime stimulant misuse than female students in university 
settings, several studies have also failed to find differences 
between males and females among college students and high 
school senior students.44,52,98,99,101,105,107,110,112 These conflict-
ing findings may be due to differences in measurement. For 
example, although Franke et al99 reported sex differences 
in lifetime prevalence of stimulant misuse for cognitive 
enhancement, the researchers did not find differences across 
males and females in past year or past month stimulant mis-
use. On the other hand, the vast majority of studies examining 
racial and ethnic differences related to stimulant misuse have 
reported that young adults, college students, and adults who 
are white are more likely to misuse stimulants than students 
of other races and ethnicities.49,53,88,91,98,99,101,113 Only one study 
reported that there were no differences in ethnicity regard-
ing prevalence of stimulant misuse; however, ,12% (n=37) 
of the study’s sample included students of color, limiting 
statistical power and thus conclusions regarding differences 
in prevalence among ethnic differences.52
Interestingly, studies examining characteristics of ado-
lescents who partake in nonmedical stimulant use indicate 
that students without plans to attend college have been 
shown to report a higher prevalence of stimulant misuse 
than those who plan to attend college, and adolescents who 
report prescription stimulant misuse may be less likely to 
attend school.94,96 However, college students appear to be 
particularly vulnerable to stimulant misuse, and members of 
fraternities and sororities have reported higher rates of misuse 
than students unaffiliated with Greek organizations.47,101,114 
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One of the reviewed studies found that college students who 
are upper classmen or live off-campus may be more likely to 
engage in nonmedical stimulant use.90 Additional correlates 
of stimulant misuse among college students have included 
affiliation with a Jewish religion, perceiving stimulant use 
as normative, and engaging in problematic weight loss 
strategies.100,101,115 Weight loss, however, may not be unique to 
college students, as adolescent prescription stimulant misus-
ers have been found to be more likely to have an eating dis-
order than students who did not misuse stimulants.96 Finally, 
all types of students (adolescents, adults, and medical) 
performing worse academically appear to be more likely to 
engage in nonmedical prescription stimulant use.56,99,101,105 
Indeed, this review found that the most commonly reported 
reasons university students take prescription stimulants are 
related to academics, and studies suggest that during periods 
of high academic stress, college students may be more likely 
to use prescription stimulants, as indicated by self-report 
measures and by measurements of stimulant levels in campus 
wastewater samples.49,54,56,105,108,110,113,115
It is not surprising, then, that procrastination and difficulty 
with time management have also been shown to relate to stim-
ulant misuse among college students.115 Further, stimulant 
misuse among college students has been shown to relate to 
higher levels of hyperactivity, sensation seeking, depression, 
internal restlessness, and psychological distress and lower 
levels of premeditation.44,58,104,114,116 ADHD diagnoses and 
symptoms may also relate to stimulant misuse.  Adolescents, 
college students, and adults diagnosed with ADHD have 
reported higher levels of prescription stimulant misuse than 
students without ADHD, and ADHD symptoms have been 
shown to correlate with nonmedical use of prescription 
stimulants.57,84,95,117 It is important to note, however, that stud-
ies suggest that the vast majority of individuals with ADHD 
do not misuse or divert their stimulant medications.84
The studies included in the present review also indicate 
that in addition to ADHD, diagnoses of conduct disorder 
and SUD are associated with increased nonmedical pre-
scription stimulant use and diversion in adolescents and 
adults.84 Illicit drug use among adolescent and university 
students is also associated with misuse of prescription 
stimulants.52,56,90,91,93,98,101,103,104,107,115,118,119
Several studies in the current review assessed student 
perspectives on prescription stimulant misuse, and findings 
revealed that students’ opinions on the ethical implica-
tions of taking illicit prescription stimulant medications to 
enhance academic outcomes are mixed. For example, Bossaer 
et al108 reported that health care students were split between 
 considering stimulant misuse to be academically dishonest 
and proffering unfair academic advantages. Similarly, half of 
the medical students sampled by Emanuel et al107 perceived 
stimulant misuse to be a problem, but 20% did not. Students 
who report engaging in stimulant misuse, however, may feel 
less conflicted regarding ethical implications. For example, 
Judson and Langdon48 reported that compared with nonillicit 
users, illicit users demonstrated fewer concerns regarding the 
safety and ethics of using stimulant medication.
Whether or not students consider their decision to 
engage in stimulant misuse to be ethical, students misusing 
stimulants appear to expect positive outcomes.107,116 Indeed, 
students who have reported taking stimulant medications 
illicitly have endorsed feeling a reduction in fatigue and 
improvement in cognition and memory after taking pre-
scription  stimulants.54 The present findings also indicate 
that students who misuse tend to perceive the benefits as 
outweighing the risks, despite the fact that little is known 
about the physiological and cognitive effects of prescription 
stimulant medications among populations without ADHD.49 
Two of the reviewed studies suggest that individuals mis-
using stimulants may be more likely to take short-acting 
agents than long-acting agents. Wilens et al84 and Bright,97 
for example, reported that adolescents and adults were 
more likely to misuse short-acting agents than long-acting 
agents, suggesting that immediate-release agents have more 
potential for abuse. Results were mixed regarding the most 
commonly misused fast-acting stimulant, with Ritalin (MPH) 
more likely to be misused than Adderall among adults, but 
nearly 12% of college students reported misusing Adderall 
compared with 8.5% misusing Ritalin.88,115
Discussion
effectiveness of ADHD treatment options
Studies included in this review revealed that the medical use 
of prescription stimulants is efficacious in reducing ADHD 
symptoms and may improve cognitive and psychosocial 
outcomes in individuals diagnosed with ADHD.  Specifically, 
research investigating LDX in comparison with placebo 
consistently found LDX efficacious across 30, 50, and 
70 mg/day. Two studies, however, found that higher doses 
related to greater improvements in overall functioning.37,62 
Most notably, the present findings support that LDX is effec-
tive for reducing ADHD symptomatology across different 
ages.37,61,62 Among adults with ADHD, LDX was also found 
to positively affect executive functions, quality of life, and 
performance productivity.35,64,66 Additionally, LDX has been 
found to be effective in reducing ADHD symptoms with 
individuals with comorbid depression and SUD.63 Although 
these results are encouraging, it is important to note that most 
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studies did report negative side effects from LDX, such as 
decreased appetite, weight loss, and nasal congestion. More 
severe side effects, however, including tachycardia, increased 
blood pressure/hypertension, and anxiety, were reported 
by ,5% of the included study samples, and no individuals 
died while participating in these studies.
Similar to those investigating LDX, studies examining the 
efficacy of MPH and D-AMP consistently found such treatment 
options to be associated with fewer ADHD symptoms compared 
with placebo. These positive effects were found among long-
acting and short-acting stimulant medications, and one study 
reported similar effects for both males and females.78 Although 
higher doses generally proved to be more effective at reducing 
ADHD symptoms, low to moderate doses of stimulants may 
also be effective at reducing ADHD symptomatology.70,74,76 
Such treatment options examined in this review were associ-
ated with enhanced cognitive performance, executive function-
ing, and quality of life and fewer emotional symptoms.68,77,81 
Although MPH and D-AMP have proved to be efficacious in 
treating ADHD symptomatology, it is important to consider 
their side effects that are similar to LDX: decreased appetite, 
weight loss, headache, insomnia, abdominal pain, dizziness, 
nervousness, emotional lability, and dry mouth. Although rare, 
more severe side effects of these medications have included 
psychosis, seizures, and cardiac events such as tachycardia, 
hypertension, myocardial infarction, and sudden death.120
Overall, however, these results are consistent with the 
child literature indicating that prostimulant and stimulant 
medications, when used as prescribed, are a safe and effica-
cious treatment option for improving attention and decreas-
ing hyperactivity and impulsivity symptoms.23,34–38,40–42 What 
remains less clear, however, is whether these medications affect 
academic and work-related outcomes of adolescents and adults 
without ADHD. Although one study reported improvements 
in measured cognition from MPH and another found that 
students who misuse stimulant medication perceive positive 
academic effects,54,68 none of the studies included in the present 
review examined changes in quality of work or student grade 
or productivity after taking stimulant medications. Given that 
cognitive enhancement-related reasons are considered the 
primary motivation for college students misusing prescription 
stimulant medications, future research examining the effects of 
prescription stimulants on direct measures of academic success 
(eg, studying and concentration, grade  performance, quality of 
writing, and reading  comprehension) is warranted.
An additional area that warrants attention concerns the 
efficacy of nonstimulant medication for the reduction of 
ADHD symptoms and any potential effects for cognitive 
enhancement. The present review was unable to identify any 
studies examining nonstimulant efficacy among adults and 
adolescents meeting the required eligibility criteria. Given 
the lower abuse potential associated with nonstimulant 
 medication, use of these medications among populations 
more susceptible to diversion and misuse may be prudent.32 
Such a recommendation, however, is contingent on a dem-
onstration of the efficacy of nonstimulants among adolescent 
and adult populations most at risk for stimulant abuse.32
Finally, although prescription stimulant medication is 
considered the front line of pharmacotherapy for ADHD 
treatment in adolescents and adults, these drugs have sig-
nificant diversion and misuse potential.43 In fact, the present 
review revealed that the medical use of prescription stimu-
lants is associated with increased stimulant misuse among 
students with ADHD, with one study reporting misuse rates 
of 62.8% among participants with a valid prescription.104
Stimulant misuse
Results from the present review indicate that a significant per-
centage of adolescents and adults are engaging in nonmedical 
stimulant misuse, which is consistent with previous research 
examining college students specifically.45 Results revealed 
lifetime prevalence rates of stimulant misuse ranging from 
1.7% to 55%, with reports varying across the population 
being examined.90,91 A limitation of this body of literature is 
the dearth of studies investigating the prevalence of prescrip-
tion stimulant misuse among college students outside of the 
US, which impedes cross-cultural comparisons regarding 
prescription stimulant misuse.
Similar to previous studies examining the nonmedical use 
of stimulants, the present review revealed that estimates vary 
according to numerous variables. For example, one trend that 
has emerged is that as individuals reach higher grade levels, 
they misuse at greater rates.56,98 Although increased exposure 
to prescription stimulants may be one reason students report 
higher prevalence rates of stimulants as they increase in age, 
these findings suggest that prescription stimulants may also be 
misused more frequently as coursework becomes more chal-
lenging and academic success becomes more difficult to obtain. 
Indeed, as indicated in this review, academic  performance 
has been reported as the primary motive for this behavior. 
A critical finding, however, is that prescription stimulant mis-
use has been found to be negatively associated with academic 
performance.44,90,101 For example, Arria et al121 reported that 
college freshmen who used prescription stimulants nonmedi-
cally had poorer study skills (eg, skipped classes more often and 
spent less time studying and more time socializing) and poorer 
academic performance (GPA) in high school and college than 
students who did not endorse stimulant misuse.51
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Despite the negative relationship between academic per-
formance and stimulant misuse, most students who endorse 
the nonmedical use of stimulants perceive them as effective 
and helpful for enhancing their academic performance.49 For 
example, Weyandt et al44 found that .20% of students in their 
sample agreed or strongly agreed that the occasional nonmed-
ical use of prescription stimulants is harmless. Additionally, 
stimulant misusers may be less concerned about the safety 
and ethical implications of stimulant misuse compared with 
students who do not misuse stimulants.48 Findings suggest, 
however, that general student populations are conflicted about 
the ethical implications of stimulant misuse.
Although individuals without ADHD have endorsed 
positive effects from misusing stimulant medication, to date 
only one study has explored the effects of Adderall on college 
students without ADHD, and this study, in general, did not 
find enhancement of cognitive abilities, despite the students’ 
impression that it was improving their performance.122  Similar 
performance-enhancing impressions have been made of MPH, 
and have led to the popularity of its use among adolescents 
and college students with and without ADHD.123 In addition, 
the present review suggests that adolescents and adults are 
more likely to misuse short-acting or immediate- release 
agents compared with long-acting agents.84,97  Consistent 
with previous studies, the present review suggests that stu-
dents who are white, affiliated with a fraternity or sorority, 
engaging in other illicit drugs, and male, are more likely to 
misuse prescription stimulants.47,49,56,57,84,89,92,94,96,101,102,113,118,124 
Although some of the studies reported no sex differences, 
recently Weyandt et al45 reported on the effect sizes of sex 
differences in studies examining stimulant misuse. Cohen’s 
d effects ranged from 0.88 to 5.38, suggesting that males are 
misusing at greater rates than females.109,110,125
implications
Pharmacotherapy is the principal choice of treatment for 
ADHD among children, adolescents, college students, 
and adults.28,29 Because stimulants are the most frequently 
prescribed drug for college students with ADHD, and most 
college students with ADHD take prescription stimulants, 
more double-blind, placebo-controlled studies examining 
the effectiveness of these medications in college students 
are warranted.22 It is important to note, however, that there 
is recent evidence that prostimulants may also be effective at 
improving symptoms in individuals with ADHD.28
The present review provides evidence that college 
students with ADHD and those with a stimulant prescrip-
tion are taking part in greater levels of stimulant misuse 
compared with those without the disorder.103,104 Although 
individuals with ADHD may greatly benefit from stimulant 
medication, these prescription medications have significant 
abuse potential when they are not used as prescribed.43 All 
prescription stimulants that are used to treat ADHD are 
controlled substances; however, abuse liability varies based 
on the delivery system in which the medication activates.126 
For example, Svetlov et al123 reported that although MPH 
and AMPH have similar psychopharmacological effects, 
they do have different neurochemical mechanisms of action. 
Such differences are essential to consider, as MPH appears 
to have less rewarding abilities, lowering its chances of 
dependence, especially when taken as prescribed. A second 
example includes the requirement of enzymatic hydrolysis 
for LDX before its therapeutic effects are achieved, which 
results in a slow increase of D-AMP levels, potentially 
lowering its use for diversion or misuse.37,127 Indeed, recent 
research has examined the effects of LDX in a group of 
stimulant abusers who did not have ADHD, and found 
that intravenous doses of LDX had greater abuse-related 
disliking compared with placebo.127 Specifically, Jasinski 
and Krishnan127 administered 100 mg of LDX and 40 mg 
of D-AMP to individuals, also reporting that intravenous 
doses of D-AMP have significantly more abuse-related  liking 
effects compared with placebo. Additionally, because of its 
chemical properties, LDX cannot be ground or dissolved 
into a short-acting stimulant, which has been the stimulant 
of choice for stimulant misusers. Given the demonstrated 
effects of LDX on improving ADHD symptomology, as well 
as executive function, and its demonstrated greater abuse-
related disliking, LDX may be the ADHD medication of 
choice for college students with ADHD who are at risk for 
stimulant misuse.37,127 LDX may also be a good choice for 
prescribers working with the college student population to 
help prevent stimulant diversion among valid prescription 
holders and misuse among college students without ADHD. 
Results of this review also suggest that health care provid-
ers should inform their patients of the health and legal risks 
associated with the misuse of prescription medications, and 
monitor the use of these medications on a frequent basis. 
Lastly, health care providers involved in prescribing 
ADHD-related medications should be thoroughly trained in 
the proper assessment, diagnosis, and treatment of ADHD to 
ensure diagnostic accuracy and treatment effectiveness.
In addition to educating prescribers about the rates of 
misuse and diversion, as well as the variables associated with 
stimulant misuse, it is critical that prevention and intervention 
efforts be made amongst health care providers and educators 
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at the middle school, high school, and higher education levels. 
Further efforts should target particularly higher-risk college 
populations such as fraternities and sororities. Information 
regarding the potential side effects of stimulant medications 
taken at varying doses and by different methods (eg, snorting 
or injecting), in addition to side effects resulting from the inges-
tion of medication as prescribed, should be made available to 
students in particular. Students should also be informed of the 
dangers of coingestion of prescription stimulants with other 
substances (eg, alcohol and cocaine), and particular emphasis 
should be placed on maintaining security of their medication 
(eg, lockboxes). Students who are misusing prescription stimu-
lants without medical guidance are placing themselves at health 
and psychological risk, in addition to legal consequences for 
buying, selling, and diverting their medications.120
The inclusion of a psychoeducational component that 
focuses on inaccurate perceptions of safety surrounding 
nonmedical prescription stimulant use would be beneficial 
to intervention as well. Students who are at risk for stimulant 
misuse with academic problems can be provided with vari-
ous support, such as tutoring and structured environments 
for studying and work completion. This additional sup-
port may encourage a school culture of clear expectations, 
educational support, and effective study habits, rather than 
competitiveness. For individuals who have been  misusing 
stimulants or are inclined to misuse, it is imperative to 
discuss the motivating factors and determine any possibly 
 undiscovered psychological, social, and/or emotional prob-
lems related to misuse or the desire to misuse. By pinpointing 
and addressing the core cause of stimulant use, students can 
be provided with the resources that will directly provide them 
with benefits and alternative methods to meet their specific 
needs. Thus, students should be educated about the potential 
side effects and risks associated with prescription stimulant 
misuse, as well as encouraged to access campus resources 
for academic and psychological support.45,47
Conclusion
Results from the present review support that both stimu-
lant and prostimulant medications (including LDX, MPH, 
AMPH, and MAS), when used as prescribed, are safe and 
effective options for reducing ADHD symptoms in adoles-
cents and adults with ADHD. Preliminary studies also sug-
gest that prescription stimulants may improve psychosocial 
outcomes (eg, quality of life, self-concept, and obsessive–
compulsive symptoms) for those with ADHD. Research 
explicitly examining effects of prescription stimulants on 
academic and cognitive functioning in students without 
ADHD is sorely limited, yet the current review revealed that 
alarmingly high percentages of adolescents and adults are 
engaging in nonmedical prescription stimulant use primar-
ily for cognitive enhancement. Results of the present review 
also revealed a higher rate of prescription stimulant misuse 
among individuals with ADHD compared with individuals 
without the disorder, and that short-acting agents are more 
likely to be misused than long-acting agents. These findings 
emphasize the need for additional research concerning the 
misuse of prescription stimulants and have direct implications 
for prevention and intervention efforts to reduce prescription 
stimulant misuse among adolescents and young adults.
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